Sign In
Buy RPRX
$53.57
+0.610 (+1.15%)
At Close: Jun 22, 2026
7 Biotech Stocks to Buy on the Dip: June 2024
12:56pm, Monday, 24'th Jun 2024
Fundamentally, the biotechnology sphere enjoys a powerful catalyst: wealth without health means nothing. Yes, it's important to save money and invest for the future.
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
09:15am, Wednesday, 12'th Jun 2024
During times of turbulence and uncertainty in the markets, even when markets are at all-time highs, many investors turn to dividend-yielding stocks. These are often companies that have high free cash
June's Biotech Boom: 3 Stocks to Buy for a Summertime Surge
06:14am, Wednesday, 05'th Jun 2024
Wall Street regards the healthcare sector as a constant source of innovation, while biotechnology stands at the pinnacle of groundbreaking medical advancements. The long-term potential of robust biote
Royalty Pharma to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
04:15pm, Tuesday, 04'th Jun 2024
NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare
Royalty Pharma Announces Pricing of $1.5 Billion of Senior Unsecured Notes
05:15pm, Monday, 03'rd Jun 2024
NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today that it has priced an offering of $1.5 billion of senior unsecured notes, comprised of the following (coll
Royalty Pharma and Agios Pharmaceuticals Enter Into Vorasidenib Royalty Agreement for $905 Million
07:10am, Tuesday, 28'th May 2024
NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired an interest in Agios Pharmaceuticals' royalty on Servier's vorasidenib for $905 millio
NEW YORK and SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Cytokinetics, Incorporated (Nasdaq: CYTK) today announced they have entered into a stra
7 Dividend Stocks to Buy at a 52-Week Low
02:41pm, Monday, 20'th May 2024
On the search for high-quality stocks at low prices? Consider taking a look at dividend stocks at a 52-week low.
Royalty Pharma to Present at Upcoming Investor Conferences
08:15am, Monday, 13'th May 2024
NEW YORK, May 13, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of May:
Royalty Pharma PLC (RPRX) Q1 2024 Earnings Call Transcript
01:32pm, Thursday, 09'th May 2024
Royalty Pharma PLC (NASDAQ:RPRX ) Q1 2024 Earnings Conference Call May 9, 2024 8:00 AM ET Company Participants George Grofik - Senior Vice President & Head of Investor Relations & Communications Pablo
Royalty Pharma (RPRX) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
01:01pm, Thursday, 09'th May 2024
The headline numbers for Royalty Pharma (RPRX) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street e
Royalty Pharma (RPRX) Beats Q1 Earnings and Revenue Estimates
09:10am, Thursday, 09'th May 2024
Royalty Pharma (RPRX) came out with quarterly earnings of $0.98 per share, beating the Zacks Consensus Estimate of $0.96 per share. This compares to earnings of $1.60 per share a year ago.
Royalty Pharma to Acquire Royalty Interest in Sanofi's Frexalimab
06:45am, Thursday, 09'th May 2024
NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today that it will acquire royalties and milestones on frexalimab owned by ImmuNext, Inc. (ImmuNext) for approxim
Why Earnings Season Could Be Great for Royalty Pharma (RPRX)
09:56am, Wednesday, 08'th May 2024
Royalty Pharma (RPRX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Insights Into Royalty Pharma (RPRX) Q1: Wall Street Projections for Key Metrics
10:21am, Monday, 06'th May 2024
Besides Wall Street's top -and-bottom-line estimates for Royalty Pharma (RPRX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during
